International EECP Patient Registry Data Updated At the American College of Cardiology 2000.

Business/Health Editors

WESTBURY, NY--(BUSINESS WIRE)--March 17, 2000

Quality of life and angina results persist or

improve six months after completion of EECP therapy

Vasomedical, Inc. (Nasdaq:VASO) announced today that updated clinical outcomes from the International EECP Patient Registry (IEPR) were presented at an IEPR participants' meeting conducted during the American College of Cardiology 2000 scientific sessions in Anaheim, CA this week. The update, presented by members of the IEPR Steering Committee from the Epidemiology Data Center, University of Pittsburgh Graduate School of Public Health, showed that at six months following EECP therapy, quality of life measures were statistically the same as at the completion of therapy. In addition, 82% of patients reported the same or less angina at the end as at the beginning of the same six-month follow-up period.

The University of Pittsburgh Graduate School of Public Health is a nationally respected registry center, administrating numerous medical registries. With nearly 2,200 patients enrolled to date, the IEPR has grown significantly from the 1,512 patients reported at the AHA meeting in November 1999. The IEPR has a planned total enrollment of 5,000 patients.

The data were presented in four periods of six months each, covering the two-year duration of the registry. In the most recent six-month group, consistent with previous reports, angina decreased by at least one Canadian Cardiovascular Society Classification (CCSC) in more than 70 % of patients, and by at least two classifications in nearly 40% of patients. The average CCSC functional classification was 3.1 before EECP therapy, improving to an average of 1.7 following EECP therapy. Quality of life data were also positive, with only 17% of patients reporting good quality of life before EECP therapy and approximately 48% reporting this level following EECP therapy. In this same group, over 54% of patients were able to discontinue their use of nitroglycerine.

"We are particularly pleased to note that registry data indicate that quality of life and angina improvements persist at six months following EECP therapy," commented D. Michael Deignan, President and CEO of Vasomedical. "The IEPR continues to provide significant insights into clinical outcomes of EECP therapy in the community-based EECP centers participating in the registry. It is a valuable source of current data for research leading to future studies, presentations, and publications which will contribute further to our understanding and acceptance of EECP therapy."

Vasomedical, Inc. is primarily engaged in designing, manufacturing, marketing and supporting external counterpulsation systems based on the company's proprietary technology. EECP(R) is a registered trademark for Vasomedical's enhanced external counterpulsation system. This system is now in use at major medical centers, including the Mayo Clinic, the Ochsner Foundation Hospital and the Miami Heart Institute, as well as medical centers affiliated with SUNY at Stony Brook, Columbia University, the University of Pittsburgh, the University of California San Diego, the University of California San Francisco, and the University of Virginia. The company provides hospitals, clinics and private practices EECP(R) equipment, treatment guidance and a staff training and maintenance program to ensure optimal patient outcomes.

Except for historical information contained in this release, the matters discussed are forward looking statements that involve risks and uncertainties. When used in this release, words such as "anticipate," "believe," "estimate," "expect" and "intend" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the impact of competitive products and pricing; capacity and supply constraints or difficulties; product development, commercialization or technological difficulties; the regulatory and trade environment; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to revise any forward-looking statements as a result of future events or developments.